Abstract 2136P
Background
Prostate cancer (PC) patients face treatment-related sequelae that affect their health and quality of life. The PCSC Program was created in 2013 and is located in the Vancouver Prostate Centre’s urology clinic. It is a clinical, educational, and research-based program that addresses challenges experienced by PC patients from the time of diagnosis onward. The program consists of 8 “modules” listed in the table.
Methods
We describe the operational details of the PCSC Program and its metrics.
Results
A Medical Director and Program Manager set the mission, oversee the day-to-day operations, and hire and manage the allied health clinicians and support staff. Office/clinic space is rotated during the week to accommodate a sexual health RN (1.4 FTE), 2 pelvic floor physiotherapists, a nurse practitioner, a registered dietitian, a clinical exercise physiologist (all 0.2 FTE), and a clinical counsellor (0.4 FTE). As of 05/2023, 3351 pts have registered for this no-cost program (Table). In 4/2020, the real-time group education sessions and clinic appointments transitioned from in-person to a hybrid with virtual options enabling the participation of patients from throughout British Columbia.
Table: 2136P
Attendance at PCSC modules for 3351 registrants from 2013 to May 2023
Modules | Attendees, n | Group education*, n (# sessions) | Clinic appointments, n (# appointments) |
Introduction to PC and primary treatment options | 945 | 955 (159) | not applicable |
Managing sexual function and intimacy | 1745 | 844 (122) | 1519 (6109) |
Management of side effects of ADT | 443 | 376 (25) | 212 (313) |
Pelvic floor physiotherapy for incontinence | 1304 | 910 (97) | 594 (2382) |
Counselling | 444 | not applicable | 444 (1629) |
Metastatic disease management | 85 | 87 (30) | not applicable |
Nutrition | 742 | 195 (31) | 361 (593) |
Exercise | 826 | 455 (70) | 674 (2167) |
*Some attendees attended the group education sessions more than once.
Conclusions
The need for PC supportive care is well recognized but may be challenging to offer when the services are fragmented and time-consuming for clinicians or staff to arrange. All modules offered by the PCSC Program can be accessed with one registration. It is convenient for patients because it is housed in one location, which also facilitates communication across disciplines. We attribute the success of our program to this model and our team approach to the individual patient’s needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prostate Cancer Supportive Care Program.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07